Patients Suitable for a Liver TransplantLT 65+NCT04754503
Survival and Quality of Life After Liver Transplantation in Patients Aged 65 and Over
An observational study of Patients Suitable for a Liver Transplant, run by Gérond'if at 1 site in France.
Trial summary
The main objective of this non-interventional, single-center study is to assess survival and associated factors at 1 year in patients aged 65 and over who received liver transplantation Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Patients Suitable for a Liver Transplant
- How many people
- 8 participants
- Where
- 1 siteFrance
- Study dates
- 9 Apr 2021to 17 Jan 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: All patients over 65 years of age who are candidates for a liver transplant at the participating center during the study period.
Who may be able to join
- Candidates for liver transplantation
- Having expressed non-oppostion to his participation in study and documented in his medical file
- With social coverage
Who cannot join
- Emergency transplant patients
- Patient already included in another study
- Patient under guardianship or curatorship
- Expressing his opposition to participate in the study
Trial locations and contacts
1 site in 1 country.
France1 site
Geriatric Department, Paul Brousse Hospital
Villejuif, Île-de-France Region, 94804
About this study
The main objective of this non-interventional, single-center study is to assess survival and associated factors at 1 year in patients aged 65 and over who received liver transplantation
Read the detailed description
The expected benefits of this study are to identify the preoperative risk factors of mortality from liver transplant failure in patients aged 65 and over (90-day mortality and 1 and 3-year survival) will allow better selection. candidates for this age group. In the current context of organ shortage, this study should make it possible to reduce the number of risky transplants and thus improve the allocation of grafts.Inclusion of patients who meet the inclusion criteria will be carried out during their hospitalization in the surgical department of the hepato-bilary center.
Included patients will receive a standardized geriatric assessment in addition to the usual assessment for a liver transplant.
The geriatric assessment will be carried out and conducted as follows: geriatric scores and quality of life questionnaires. Two geriatricians will perform the physical examination and blindly estimate each other's probability of survival at 90 days using a Likert scale.
Geriatricians will be blinded to hepatic data (reasons for transplantation). The consultation as well as the completion of the questionnaire will be carried out during the pre-transplantation assessment.
Survival and quality of life will be assessed at 3 and 12 months post-transplantaion.
- Conditions
- Patients Suitable for a Liver Transplant
- Keywords
- liver transplant
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of survival and quality of life after liver transplantation according to the quality of life score
Measured: 12 Months
Secondary outcomes (1)
Detecting depression in the elderly according the Geriatric Depression Scale (GDS)
Measured: 12 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Feb 2021
- Study start9 Apr 2021
- Primary completion11 May 2022
- Study completion17 Jan 2023
Why it stopped: Due to recruitment difficulties, it has been decided to stop patient enrollment.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Patients Suitable for a Liver TransplantStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- Gérond'if
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Duron Emmanuelle, MD PhD, Study chair, Geriatric Department, Paul Brousse Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04754503
- Sponsor's protocol ID
- 2020-A03063-36
- Acronym
- LT 65+
- Status last verified
- Sep 2026
- First submitted
- 12 Feb 2021
- Last updated
- 23 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Survival and Quality of Life After Liver Transplantation in Patients Aged 65 and Over
- ClinicalTrials.gov ID
- NCT04754503
- Acronym / sponsor ID
- LT 65+ / 2020-A03063-36
- Conditions
- Patients Suitable for a Liver Transplant
- Keywords
- liver transplant
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Due to recruitment difficulties, it has been decided to stop patient enrollment.
- Enrolment
- 8 participants (actual)
- Lead sponsor
- Gérond'ifUniversity, hospital or other
- Study start
- 9 Apr 2021 (actual)
- Primary completion
- 11 May 2022 (actual)
- Study completion
- 17 Jan 2023 (actual)
- First posted
- 15 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of this non-interventional, single-center study is to assess survival and associated factors at 1 year in patients aged 65 and over who received liver transplantation
Detailed description
The expected benefits of this study are to identify the preoperative risk factors of mortality from liver transplant failure in patients aged 65 and over (90-day mortality and 1 and 3-year survival) will allow better selection. candidates for this age group. In the current context of organ shortage, this study should make it possible to reduce the number of risky transplants and thus improve the allocation of grafts.Inclusion of patients who meet the inclusion criteria will be carried out during their hospitalization in the surgical department of the hepato-bilary center.
Included patients will receive a standardized geriatric assessment in addition to the usual assessment for a liver transplant.
The geriatric assessment will be carried out and conducted as follows: geriatric scores and quality of life questionnaires. Two geriatricians will perform the physical examination and blindly estimate each other's probability of survival at 90 days using a Likert scale.
Geriatricians will be blinded to hepatic data (reasons for transplantation). The consultation as well as the completion of the questionnaire will be carried out during the pre-transplantation assessment.
Survival and quality of life will be assessed at 3 and 12 months post-transplantaion.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- All patients over 65 years of age who are candidates for a liver transplant at the participating center during the study period.
Key inclusion criteria (3 listed)
- Candidates for liver transplantation
- Having expressed non-oppostion to his participation in study and documented in his medical file
- With social coverage
Key exclusion criteria (4 listed)
- Emergency transplant patients
- Patient already included in another study
- Patient under guardianship or curatorship
- Expressing his opposition to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Assessment of survival and quality of life after liver transplantation according to the quality of life score
Time frame: 12 Months
1 secondary outcome
Detecting depression in the elderly according the Geriatric Depression Scale (GDS)
Time frame: 12 Months
Results and safety
The study was stopped early (reason given: Due to recruitment difficulties, it has been decided to stop patient enrollment.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Duron Emmanuelle, MD PhD study chair
Geriatric Department, Paul Brousse Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Patients Suitable for a Liver Transplant, run by Gérond'if at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Due to recruitment difficulties, it has been decided to stop patient enrollment.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of survival and quality of life after liver transplantation according to the quality of life score (time frame: 12 Months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026.